Search | Clinical Trials Finder

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Interventions: Immune globulin (human) 10% solution for intravenous administration; Biological
Lead sponsor: Kedrion S.p.A.; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Stamford, Connecticut • Miami, Florida • Tampa, Florida + 2 more

Conditions: Kidney Transplantation in Highly Sensitized Patients
Interventions: Imlifidase, PLEX, IVIg, Anti-CD20 antibodies, Eculizumab, Remain on wait list; Drug · Procedure · Other
Lead sponsor: Hansa Biopharma AB; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 25
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more

Conditions: Hepatitis C Infection, Viruses, Hepatocellular Carcinoma, Hepatitis, Viral, Human, Liver Cirrhosis
Interventions: Civacir® 10%; Biological
Lead sponsor: Biotest Pharmaceuticals Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 23
States / cities: Los Angeles, California • San Francisco, California • Miami, Florida + 15 more

Conditions: Middle East Respiratory Syndrome Coronavirus
Interventions: SAB-301, Normal (9%) Saline; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Primary Immunodeficiency
Interventions: GAMUNEX-C; Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 2 Years to 16 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Los Angeles, California • Centennial, Colorado • Hollywood, Florida + 1 more

Conditions: Idiopathic Thrombocytopenic Purpura
Interventions: IGIV3I Grifols 10%; Biological
Lead sponsor: Grifols Biologicals, LLC; Industry
Eligibility: 3 Years to 70 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 31
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 26 more

Conditions: Hypogammaglobulinemia, Lung Transplantation
Interventions: IVIG, Placebo; Drug · Other
Lead sponsor: Columbia University; Other
Eligibility: 12 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Multifocal Motor Neuropathy
Interventions: Immune Globulin Intravenous (human), 10%, 0.25% human albumin solution (Placebo); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 12
States / cities: Los Angeles, California • Stanford, California • Centennial, Colorado + 9 more

Conditions: Miscarriage, Recurrent, Abortion, Habitual
Interventions: Gamimune N or Gamunex 10%, normal saline; Biological · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Primary Immunodeficiency Diseases (PID)
Interventions: Immune Globulin Intravenous (Human), 10%; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 24 Months and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 9
States / cities: Los Angeles, California • Centennial, Colorado • North Palm Beach, Florida + 6 more

Conditions: Systemic Sclerosis, Diffuse Scleroderma
Interventions: Privigen; Biological
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Immunologic Deficiency Syndrome, Agammaglobulinemia, Severe Combined Immunodeficiency, Wiskott-Aldrich Syndrome, Common Variable Immunodeficiency
Interventions: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified, Dextrose, 5% in Water; Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 9
States / cities: Birmingham, Alabama • Denver, Colorado • Washington D.C., District of Columbia + 6 more

Conditions: Pompe Disease
Interventions: Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase, Rapamycin, saline, Rituxan, Diphenhydramine, Acetaminophen, Lidocaine, LMX 4 Topical Cream; Genetic · Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 50 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Alzheimer´s Disease
Interventions: Immune Globulin Intravenous (Human), 10% Solution, Human albumin 0.25%; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 34 more

Conditions: Alzheimer´s Disease
Interventions: Immune Globulin Intravenous (Human), 10% (IGIV, 10%); Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 51 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Mucocutaneous Lymph Node Syndrome
Interventions: IVIG, Infliximab; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: Up to 17 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 29
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 24 more

Conditions: Hematologic Malignancies
Interventions: Immune Globulin Infusion (Human), 10% Solution, Anti-CD19 CAR T Cells Preparation, Saline, Biospecimen Collection, Survey Administration, Electronic Health Record Review; Biological · Other · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: Duarte, California • Miami, Florida • Tampa, Florida + 4 more

Conditions: Purpura, Thrombocytopenic, Idiopathic
Interventions: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified; Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 1
States / cities: New York, New York

Conditions: Primary Immunodeficiency Diseases (PID)
Interventions: HYQVIA; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 2 Years to 15 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 19
States / cities: Birmingham, Alabama • Hartford, Connecticut • Miami, Florida + 15 more

Conditions: Mild Cognitive Impairment
Interventions: Octagam 10%; Biological
Lead sponsor: Sutter Health; Other
Eligibility: 50 Years to 84 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Mild Cognitive Impairment
Interventions: NewGam 10% IVIG, Placebo; Drug · Other
Lead sponsor: Sutter Health; Other
Eligibility: 50 Years to 84 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Immunologic Deficiency Syndrome
Interventions: Immune Globulin Intravenous (Human); Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 13 Years to 75 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 6
States / cities: Irvine, California • Los Angeles, California • Atlanta, Georgia + 3 more

Conditions: Primary Immunodeficiency Disease
Interventions: IgG Next Generation (BT595); Biological
Lead sponsor: Biotest; Industry
Eligibility: 2 Years to 75 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 9
States / cities: Birmingham, Alabama • Los Angeles, California • Centennial, Colorado + 6 more

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions: HYQVIA; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Phoenix, Arizona

Search by objective public record fields.

A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults

Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency

IGIV Study for Chronic ITP Patients Ages 3-70

Intravenous Immunoglobulin (IVIG) in Lung Transplantation

Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy

Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage

Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects

IVIG Treatment in Systemic Sclerosis

Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients

Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease

Phase 3 IGIV, 10% in Alzheimer´s Disease

Long-Term Study of IGIV, 10% in Alzheimer´s Disease

KIDCARE (Kawasaki Disease Comparative Effectiveness Trial)

IVIG for Infection Prevention After CAR-T-Cell Therapy

Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP

Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects

Effect of IVIG on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer Disease

Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment

A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency

Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID

Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP